Parasitic myocarditis

Article written and reviewed by Dr Luca Moretti

Parasitic myocarditis comprises a heterogeneous group of diseases in which protozoa or helminths reach the heart or cause myocardial injury through the immune response and systemic consequences of infection. It is not a single therapeutic entity: epidemiology, life cycle, tropism, immune status and phase of parasitic infection determine testing and treatment; a generic diagnosis of “cardiac parasitosis” is therefore insufficient in clinically relevant cases.

The greatest global burden is caused by Trypanosoma cruzi, responsible for Chagas heart disease, but inflammatory cardiac involvement may accompany toxoplasmosis, trichinellosis and African trypanosomiasis. Other parasites more often produce cysts, masses, emboli, pulmonary hypertension or systemic injury rather than true myocarditis; separating these phenotypes prevents every cardiac abnormality observed during infection from being attributed to myocardial inflammation.

The apparent rarity also reflects diagnostic difficulty. The heart is biopsied only in the most severe presentations, lesions may be focal, and many patients have fever, tachycardia and elevated troponin that can be explained by sepsis, anemia, hypoxia or renal failure. A temporal relationship does not prove cardiac invasion, while demonstration of the parasite in another organ does not automatically establish the cause of ventricular dysfunction.

The history must reconstruct the entire epidemiologic lifetime: country of birth, travel, housing, vectors, water, raw meat, animal contact, transfusions, transplantation and immunosuppressive treatments. Some infections remain latent for decades and reactivate when cellular immunity declines; others cause cardiac injury during initial larval migration. The date of the most recent exposure does not necessarily coincide with the biological onset of heart disease.

Management requires collaboration among cardiology, infectious diseases, microbiology, pathology and, in fragile patients, intensive care or transplant medicine; the priority is to support perfusion and rhythm without losing the opportunity to identify the pathogen. Empiric immunosuppression, appropriate in some noninfectious histotypes, may increase parasite burden and dissemination here and must be weighed against hemodynamic urgency.

Etiology, Pathogenesis and Pathophysiology

Toxoplasma gondii persists as tissue cysts after primary infection. Clinically evident cardiac involvement is rare in immunocompetent people, whereas advanced AIDS, transplantation and immunosuppression may permit reactivation with tachyzoites, necrosis and an inflammatory infiltrate. Myocarditis, encephalitis, pneumonia, chorioretinitis and disseminated disease may coexist, and an extracardiac site often provides a less risky diagnostic sample than myocardium.

In trichinellosis, larvae ingested with contaminated meat pass through the intestine and circulation before encysting in striated muscle. The heart is not a site of mature encystment comparable with skeletal muscle; cardiac injury results from larval passage, inflammation, eosinophilia, vasculitis and metabolic abnormalities. Periorbital edema, myalgia, fever, eosinophilia and elevated muscle enzymes make the context recognizable, but myocardial severity does not perfectly track the eosinophil count.

African trypanosomes, T. brucei gambiense and T. brucei rhodesiense, may be associated with ECG abnormalities, pericardial effusion and myocardial injury during the hemolymphatic or meningoencephalitic phase. Inflammation, parasite presence and the immune response contribute to varying degrees. The phenotype differs from chronic Chagas disease: the same apical aneurysms are not typical, and therapy depends on species and neurologic stage.

Trypanosoma cruzi invades numerous cell types, persists at low density and sustains inflammation, microangiopathy, denervation and fibrosis. During the acute phase it may cause diffuse myocarditis, whereas after years chronic heart disease develops conduction disturbances, aneurysms, ventricular tachycardia, thromboembolism and heart failure. Its importance justifies a dedicated pathway distinct from the other infectious forms.

Severe malaria causes tachycardia, hypotension, anemia, acidosis, hypoxia and microcirculatory dysfunction; troponin elevation or ventricular abnormalities do not automatically indicate myocarditis. Parasite sequestration, inflammation and hemodynamic effects may injure the heart, but documented primary myocarditis is uncommon; the same principle applies to many systemic parasitic diseases in which the predominant cardiovascular phenotype is not inflammatory.

Cardiac cysticercosis and echinococcosis mainly generate intramyocardial or pericardial cysts, masses, obstruction, arrhythmias, rupture and embolization; inflammation increases when a cyst degenerates or ruptures, but the anatomic problem remains central and changes the surgical strategy. In schistosomiasis, the dominant cardiovascular complication is pulmonary hypertension from vascular and hepatoportal disease, not diffuse myocarditis.

The host type alters histology and pathogen burden. An immunocompetent person may develop an intense infiltrate with few organisms, whereas a profoundly immunocompromised patient may have abundant parasites with an attenuated cellular response. Absence of eosinophilia or granulomas therefore does not exclude infection, and tissue appearance must be interpreted together with treatment, lymphocyte count and disease timing.

Myocardial injury evolves through necrosis, edema, microvascular dysfunction and scarring; focal lesions create electrical heterogeneity even with preserved ejection fraction, whereas diffuse involvement reduces output and contractile reserve. Once fibrosis is established, parasite eradication may prevent new injury without eliminating an already formed arrhythmic substrate.

The granulomatous response represents an additional containment mechanism; it may circumscribe persistent antigens but can also create nodules and scars that mimic sarcoidosis or other granulomatous myocarditis. Negative stains and PCR do not eliminate an infectious agent when burden is low or the sample is small; before immunosuppression, a richer extracardiac site is therefore sought and endemic exposures are reconstructed.

Clinical Manifestations

The cardiac presentation ranges from subclinical ECG abnormalities to chest pain, dyspnea, palpitations, syncope, heart failure and shock. Fever and systemic signs may dominate and make tachycardia appear proportionate to the infection, but an excessive rate, a new conduction disturbance or dynamic troponin elevation requires targeted assessment. Normal systolic function does not exclude edema or electrical risk.

In toxoplasmosis in immunocompromised patients, the presentation may progress rapidly, with biventricular failure, arrhythmias or sudden death; headache, focal neurologic deficits, seizures, ocular abnormalities and pulmonary infiltrates suggest dissemination. In transplant recipients, the problem includes primary infection transmitted by the organ, reactivation in the recipient and differential diagnosis with rejection, conditions that require opposite immunologic decisions.

Trichinellosis generally begins with gastrointestinal symptoms, followed by fever, facial edema, myalgia, weakness and eosinophilia during dissemination; cardiac involvement may present with pain, ST-T abnormalities, tachyarrhythmias, heart failure and, rarely, shock. Skeletal-muscle injury may raise creatine kinase and confound interpretation of troponin T, making integrated interpretation of biomarkers useful.

In African trypanosomiasis, systemic signs, lymphadenopathy, recurrent fever and pruritus are common, followed in the late phase by sleep disturbance and neurologic manifestations. An abnormal ECG and pericardial effusion may occur without severe clinical failure, but an acute form caused by T. b. rhodesiense may deteriorate more rapidly; geographic origin and the tempo of progression help distinguish the two subspecies.

Chest pain may mimic an acute coronary syndrome and cardiac magnetic resonance may show edema and nonischemic late gadolinium enhancement. Emboli, vasculitis, anemia and hypotension may nevertheless cause true ischemia, while a cyst may compress a coronary artery; anatomic assessment is not omitted simply because a parasitic infection has been diagnosed.

Arrhythmias include ectopy, ventricular tachycardia, atrial fibrillation and bradyarrhythmias; their frequency depends on the distribution of injury. Syncope and presyncope are risk signals, especially in the presence of scar, conduction block or dysfunction; telemetry and prolonged monitoring are adapted to the disease phase because a single ECG may fail to capture intermittent events.

Extracardiac dissemination is part of the presentation rather than an incidental comorbidity; the brain, retina, lungs, muscle, skin, intestine, liver and blood may provide decisive clues and determine therapeutic urgency. A treatment that controls cardiac disease but does not penetrate the central nervous system may be inadequate for the infection as a whole.

In children and during pregnancy, probability, transmission, toxicity and drug choice change; congenital toxoplasmosis and congenital Chagas disease require dedicated algorithms, while some therapies are teratogenic or insufficiently studied. Specialist counseling must coordinate maternal benefit, fetal risk and the need for diagnosis in the newborn.

Pericardial effusion may accompany trypanosomiasis, toxoplasmosis and inflammatory reactions, but tamponade and pericarditis do not demonstrate myocardial invasion. Positional pain with elevated troponin defines a combined phenotype; the relative pericardial and myocardial components determine use of anti-inflammatory drugs, physical activity and monitoring. In cardiac cysts, an effusion may instead signal fissuring or rupture and require an anatomic emergency response.

Investigations and Diagnosis

Diagnosis proceeds along two parallel axes: demonstrating myocardial injury and identifying the responsible parasitic infection. ECG, troponin, natriuretic peptides, echocardiography and cardiac magnetic resonance characterize the heart; microscopy, serology, antigen testing, PCR and histology depend on the pathogen. No single result replaces consistency among exposure, biological phase, organs involved and response to treatment.

A complete blood count with differential looks for eosinophilia, anemia, thrombocytopenia and host-related abnormalities; eosinophils support trichinellosis or other helminth infections but may be normal early, reduced by corticosteroids or absent during immunosuppression. A high value also requires differential diagnosis with eosinophilic myocarditis, drug reactions, EGPA and clonal syndromes.

For toxoplasmosis, IgG documents remote exposure and isolated IgM requires confirmation; in immunocompromised patients serology may be poorly informative. PCR on blood, cerebrospinal fluid or other samples and histologic demonstration of tachyzoites increase certainty, but sensitivity varies according to site and therapy. Neuroimaging and ophthalmologic assessment are often as essential as cardiac tests.

In trichinellosis, dietary history, clinical syndrome, eosinophilia and seroconversion build the diagnosis; antibodies may appear after symptom onset, so an early negative test does not close the case. Muscle biopsy is reserved for uncertain situations and may show larvae, whereas cardiac biopsy is rarely necessary when the systemic presentation is convincing.

African trypanosomiasis requires demonstration of the parasite in blood, lymph-node aspirate or other samples and subsequent neurologic staging according to species and control program. Serologic screening tests do not have the same role in every region; ECG and echocardiography document cardiac involvement without replacing staging, which determines the ability of the chosen drug to reach the central nervous system.

Echocardiography assesses biventricular function, effusion, pressures, thrombi and focal lesions; contrast or advanced imaging assists with cysts and aneurysms. Cardiac magnetic resonance identifies edema, necrosis and scar but does not identify the species; a nonischemic distribution supports myocarditis, whereas masses or cysts require computed tomography, dedicated sequences and multidisciplinary planning.

Endomyocardial biopsy is indicated when shock, arrhythmias, conduction blocks or failure to respond make it necessary to distinguish infection, rejection, eosinophilic myocarditis and other treatable forms. Multiple samples are allocated to histology, immunohistochemistry, stains, microscopy and molecular tests agreed upon before the procedure; inappropriate fixation may make the intended investigation impossible.

When an accessible extracardiac lesion exists, biopsy of muscle, skin, lymph node or another organ may provide greater yield and lower risk. The result must still explain the cardiac phenotype: confirmed cerebral toxoplasmosis makes myocarditis plausible but does not exclude ischemia, drug toxicity or sepsis. Final diagnosis remains integrated.

The differential diagnosis includes viral or bacterial myocarditis, acute coronary syndrome, endocarditis, genetic cardiomyopathy, Takotsubo syndrome, rejection, hypersensitivity and drug-induced injury. Travelers may have more than one infection, whereas in transplant recipients prophylaxis and negative tests modify probability without reducing it to zero; every unexpected result must reopen the causal model.

Test performance depends on disease phase: blood microscopy is more productive during acute parasitemia, whereas serology gains value during chronic persistence. Antiparasitic treatment already started reduces the sensitivity of direct detection; immunosuppression may instead increase pathogen burden and facilitate PCR without making the procedure clinically safe. Date, specimen, treatment and method must accompany every result in the report.

Treatment and Prognosis

Treatment combines cardiac stabilization and pathogen-specific antiparasitic therapy. Shock and arrhythmias are managed immediately with monitoring, ventilation, vasoactive drugs and circulatory support when necessary; samples are collected at the same time before treatment reduces diagnostic yield. There is no empiric drug that safely covers all protozoa and helminths.

Severe toxoplasmosis is treated with regimens active against tachyzoites, traditionally pyrimethamine, sulfadiazine and folinic acid, with alternatives determined by site, allergies, organ function and availability. In patients with HIV or transplantation, treatment duration, maintenance therapy and immune reconstitution are crucial; complete blood count, renal function and liver function are monitored for toxicity and interactions.

Trichinellosis is treated with albendazole or mebendazole, with greater biological efficacy when started during the intestinal or migratory phase. Corticosteroids may accompany severe forms with cardiac, neurologic or pulmonary involvement but do not replace anthelmintic therapy; the decision accounts for the fact that larval killing and the inflammatory response may temporarily change symptoms.

African trypanosomiasis requires drugs selected by subspecies and stage according to international programs and guidelines; fexinidazole, pentamidine, suramin, nifurtimox-eflornithine and melarsoprol are not interchangeable. Toxicity may be considerable and treatment is coordinated by expert centers; parasitologic and neurologic control guides follow-up beyond cardiac recovery.

Chagas disease is treated with benznidazole or nifurtimox when indicated, while arrhythmias, conduction blocks, thromboembolism and heart failure receive independent cardiac treatment. In advanced chronic cardiomyopathy, reducing parasite burden does not repair scar; the etiologic and prognostic objectives must be explained separately to the patient.

Heart failure is treated according to phenotype and hemodynamic stability, with caution regarding hypotension, renal failure, interactions and electrolyte disturbances caused by antiparasitic drugs. Acute arrhythmias require correction of fever, hypoxia and electrolyte abnormalities in addition to drugs or cardioversion; pacemakers and defibrillators are considered after accounting for reversibility and residual risk.

Immunosuppression is not prescribed solely because cardiac magnetic resonance shows edema; it may be necessary to control a dangerous inflammatory response in specific parasitic diseases, but must be combined with causal therapy and pathogen-burden surveillance. In transplant recipients, calibrated reduction of immunosuppression may facilitate control while balancing rejection risk.

Prognosis is favorable when a treatable infection is recognized before shock or extensive scar develops. Late diagnosis, persistent immunosuppression, neurologic involvement, biventricular dysfunction, ventricular tachycardia and inability to eradicate the parasite worsen outcome; recovery of ejection fraction does not always eliminate arrhythmic risk.

Follow-up integrates symptoms, ECG, cardiac function, biomarkers and microbiological control; duration is not uniform: resolved trichinellosis and a latent parasitic infection capable of reactivation require different strategies. Before new immunosuppression, pregnancy or transplantation, the risks of persistence and transmission are reassessed.

Assessment of response is not limited to test conversion to negative. In some chronic infections, molecular tests may fluctuate or remain positive at low burden, whereas in others antibodies persist after cure and are not tests of cure. Clinical status, organs involved, function, rhythm and the pathogen-specific method are combined, avoiding prolongation of toxic therapy solely because of a marker that does not measure viability.

Complications

Shock may result from ventricular failure, vasoplegia, hypovolemia or combinations of these mechanisms. Serial assessment of cardiac output prevents treatment of cardiogenic hypoperfusion with excessive fluids or vasoplegic sepsis with inotropic therapy alone; in reversible forms, mechanical support may provide the time needed for antiparasitic treatment to act.

Ventricular arrhythmias and conduction blocks may appear during inflammation or persist within scar; tachycardia during fever should not be dismissed when it is disproportionate, irregular or accompanied by syncope. Post-acute monitoring is extended in patients with late gadolinium enhancement, reduced function or documented arrhythmias.

Ventricular thrombi, aneurysms, inflammation and immobility increase embolic risk. Indications for anticoagulation depend on the demonstrated mechanism and bleeding risk, which is particularly relevant with thrombocytopenia, cerebral lesions or liver disease; parasitic infection itself is not a universal indication.

Reactivation during chemotherapy, biologic therapy, AIDS or transplantation may be faster and more disseminated than the initial infection. An increase in molecular burden may precede symptoms and permit pre-emptive therapy in selected protocols; confusing reactivation with rejection or autoimmune disease risks harmful escalation of immunosuppression.

Treatment complications include cytopenias, hepatotoxicity, nephrotoxicity, neuropathy, pancreatitis, skin reactions and drug interactions; some regimens alter QT interval or electrolytes in an already unstable heart. Medication review, correct dosing and monitoring prevent causal therapy from becoming a second mechanism of cardiac injury.

A residual scar may sustain cardiomyopathy, functional valvular regurgitation, arrhythmias and exercise limitation even after microbiological cure. Rehabilitation, heart-failure therapy and electrical risk stratification continue independently of negative microbiological tests; the patient should understand that cure of infection and anatomic recovery are not synonymous.

Prevention concerns food safety, vector control, screening of blood and organs, treatment of people at risk and prophylaxis in immunocompromised patients when indicated. Precise information prevents both stigma and false reassurance: many parasitic infections are not transmitted through ordinary daily contact, but some have preventable congenital, transfusional or foodborne routes.

New immunosuppression changes risk even many years after the initial infection. Before transplantation, biologic drugs or chemotherapy, latent parasitic infections are sought according to origin and exposure, and prophylaxis or surveillance is then established. This step prevents heart disease attributed to treatment from actually being reactivation and allows intervention while pathogen burden is still low.